Terry Ann Burrell Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Terry Ann Burrell is Director of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 71,254 shares of RXRX, which is worth approximately $456,025. The most recent transaction as insider was on Jul 01, 2024, when has been sold 1,843 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 71.3K

0% 3M change

29.91% 12M change

Total Value Held $456,025

Terry-Ann Burrell Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 01 2024	BUY Grant, award, or other acquisition	-	1,843 Added 2.52%	71,254 Class A Common Stock
Jun 03 2024	BUY Grant, award, or other acquisition	-	13,097 Added 15.87%	69,411 Class A Common Stock
Apr 01 2024	BUY Grant, award, or other acquisition	-	1,467 Added 2.54%	56,314 Class A Common Stock
Jul 13 2023	SELL Open market or private sale	$104,182 $12.59 p/Share	8,275 Reduced 13.11%	54,847 Class A Common Stock
Jul 12 2023	SELL Open market or private sale	$1,377,545 $12.67 p/Share	108,725 Reduced 63.27%	63,122 Class A Common Stock
Jun 16 2023	BUY Grant, award, or other acquisition	-	12,612 Added 6.84%	171,847 Class A Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	1,821 Added 1.13%	159,235 Class A Common Stock
Oct 03 2022	BUY Grant, award, or other acquisition	-	1,265 Added 0.8%	157,414 Class A Common Stock
Jul 01 2022	BUY Grant, award, or other acquisition	-	1,631 Added 1.03%	156,149 Class A Common Stock
Jun 14 2022	BUY Grant, award, or other acquisition	-	18,145 Added 10.51%	154,518 Class A Common Stock
Apr 01 2022	BUY Grant, award, or other acquisition	-	1,788 Added 1.29%	136,373 Class A Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	763 Added 0.56%	134,585 Class A Common Stock
Oct 01 2021	BUY Grant, award, or other acquisition	-	629 Added 0.47%	133,822 Class A Common Stock
Jul 01 2021	BUY Grant, award, or other acquisition	-	382 Added 0.29%	133,193 Class A Common Stock
Apr 20 2021	SELL Other acquisition or disposition	-	126,561 Reduced 100.0%	0 Common Stock
Apr 20 2021	SELL Conversion of derivative security	-	6,250 Reduced 100.0%	0 Common Stock
Apr 20 2021	BUY Other acquisition or disposition	-	126,561 Added 50.0%	126,561 Class A Common Stock
Apr 20 2021	BUY Conversion of derivative security	-	6,250 Added 4.49%	132,811 Class A Common Stock
Apr 16 2021	BUY Grant, award, or other acquisition	-	6,250 Added 4.71%	126,561 Common Stock

Also insider at

BEAM

Beam Therapeutics Inc. Healthcare

Chief Financial Officer